Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.32-1.07%BTC$76,801.00-1.26%ETH$2,252.61-0.28%GOLD$3,956.60-0.33%OIL$96.26-0.21%
Smart Investors Daily
SID Premium
Biohaven Ltd. logo

NYSE · BHVN

Biohaven Ltd.

Healthcare · Biotechnology

$15.42

Down-$0.26 (-1.69%)

Updated Nov 2, 2026, 10:57 PM

SID Score

5.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.21B
P/E ratio
-1.55
Dividend yield
0.00%
52-week range
$8.03 – $18.24
Volume
3.16M
Avg. volume
3.75M

Price performance · BHVN

BHVN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

BHVN closed at $15.42 after 20 trading sessions, up 18.89% for the selected period.

Last close
$15.42
Period change
+18.89%
Period low
$10.78
Period high
$16.49
Daily close
View OHLC price history
BHVN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$15.46$16.33$15.12$15.423.16M
Oct 29, 2026$15.46$16.49$15.46$16.492.45M
Oct 28, 2026$15.11$15.87$14.955$15.523.15M
Oct 27, 2026$14.44$15.30$14.13$15.292.43M
Oct 26, 2026$13.94$14.6973$13.695$14.452.68M
Oct 23, 2026$15.215$15.37$13.83$13.884.69M
Oct 22, 2026$16.10$16.54$14.45$14.6930.51M
Oct 21, 2026$11.90$12.1647$11.625$11.751.44M
Oct 20, 2026$11.35$11.845$11.07$11.811.53M
Oct 19, 2026$11.01$11.52$10.865$11.351.69M
Oct 16, 2026$11.31$11.40$10.70$10.782.42M
Oct 15, 2026$10.95$11.66$10.94$11.431.45M
Oct 14, 2026$11.39$11.50$10.82$10.931.78M
Oct 13, 2026$11.79$11.79$11.16$11.422.43M
Oct 12, 2026$11.91$11.99$11.65$11.811.62M
Oct 9, 2026$11.90$12.27$11.745$12.081.37M
Oct 8, 2026$11.83$12.12$11.46$11.932.7M
Oct 7, 2026$11.86$12.2318$11.845$11.882.15M
Oct 6, 2026$13.00$13.04$11.88$12.083.05M
Oct 5, 2026$12.85$13.31$12.45$12.971.67M

Latest BHVN news

The latest Smart Investors Daily articles mentioning BHVN.

Stock researchCompany · Overview

BHVN research

Overview

Company profile and research snapshot.

Company profile

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.50
Implied upside
—
Analysts
—
BHVN recent ratings
DateFirmRatingTarget
Oct 30, 2026Canaccord GenuityBuy—
Oct 23, 2026RBC CapitalSector Perform—
Sep 10, 2026HC Wainwright & Co.Neutral—
Sep 8, 2026RBC CapitalSector Perform—
Aug 12, 2026Morgan StanleyOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Rheumatoid Arthritis, Psoriatic Arthritis, Atopic Dermatitis, Alopecia Areata, Ulcerative Colitis, Crohn's Disease, Myelofibrosis, Polycythemia Vera, GvHD, Vitiligo, Systemic Lupus Erythematosus, Hidradenitis Suppurativa, and others. The selected in

Yahoo · Oct 26, 2026

Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy

Biohaven Ltd. (NYSE: BHVN) (Biohaven) on Saturday presented preclinical data for BHV-1420 in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado. BHV-1420 is a novel TRAP extracellular protein degrader designed to selectively eliminate the anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies that drive membranous nephropathy (MN).

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By